Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.40 |
| ▸ | RET | P07949 | 3/20 | 0.40 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | PAK4 | O96013 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | PRKACA | P17612 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | LTK | P29376 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Toyocamycin Aglycone SCHEMBL7698538 | 0.81 | MAP3K7 (0.54) | LRRK2ROCK1MAP3K7TAB1CHUK | |
| SCHEMBL1737697 | 0.80 | CHEK1 (0.56) | LRRK2JAK3MAP3K7TAB1CHEK1 | |
| SCHEMBL9254230 | 0.80 | JAK3 (0.39) | LRRK2ROCK1JAK3MAP3K7TAB1 | |
| SCHEMBL5527750 | 0.76 | RET (0.38) | LRRK2RETFLT3ROCK1MAP3K7 | |
| SCHEMBL18844347 | 0.76 | MAP3K7 (0.38) | LRRK2RETMAP3K7TAB1CHEK1 | |
| SCHEMBL5805420 | 0.74 | RET (0.43) | LRRK2RETDAPK3MAP4K4PAK4 | |
| SCHEMBL5522155 | 0.74 | RET (0.44) | LRRK2RETABL1ADK | |
| SCHEMBL6531144 | 0.72 | RET (0.42) | LRRK2RETFLT3AURKBCHEK1 | |
| SCHEMBL3536255 | 0.72 | LRRK2 (0.58) | LRRK2FLT3CDK8MAP2K1ROCK1 | |
| SCHEMBL23735452 | 0.71 | CHEK1 (0.48) | LRRK2RETABL1CDK5CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169918-B2 | Methods for preparing 7-(2′-substituted-β-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2007-01-30 | — | — | US | claimed |
| EP-1682564-A1 | METHODS FOR PREPARING 7-(2 -SUBSTITUTED-s-D-RIBOFURANO SYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO 2,3-D|PYRIMIDINE DERIVATIVES | GENELABS TECHNOLOGIES, INC. (US) | 2006-07-26 | — | — | EP | claimed |
| US-20050215510-A1 | Methods for preparing 7-(2'-substituted-beta-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives | GENELABS TECHNOLOGIES, INC. | 2005-09-29 | — | — | US | claimed |
| WO-2005044835-A1 | METHODS FOR PREPARING 7-(2'-SUBSTITUTED-ß-D-RIBOFURANOSYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | GENELABS TECHNOLOGIES, INC. (US) | 2005-05-19 | — | — | WO | claimed |
| EP-3728282-B1 | 2'3' CYCLIC DINUCLEOTIDES WITH PHOSPHONATE BOND ACTIVATING THE STING ADAPTOR PROTEIN | INST OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR V V I (CZ) | 2023-11-22 | — | — | EP | disclosed |
| EP-3934757-B1 | 2'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF | INST OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR V V I (CZ) | 2023-02-22 | — | — | EP | disclosed |
| WO-2022260336-A2 | NUCLEOSIDE DERIVATIVE HAVING MULTI-TARGET KINASE INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING CANCER COMPRISING SAME | 퓨쳐메디신 주식회사 | 2022-12-15 | — | — | WO | disclosed |
| EP-3936514-A1 | 3'3' CYCLIC DINUCLEOTIDES WITH AN ALKENYLENE | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. (CZ) | 2022-01-12 | — | — | EP | disclosed |
| US-7169918-B2 | Methods for preparing 7-(2′-substituted-β-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-20050215510-A1 | Methods for preparing 7-(2'-substituted-beta-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives | GENELABS TECHNOLOGIES, INC. | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215510-A1 | Methods for preparing 7-(2'-substituted-beta-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives | HAVCR2, NR4A3, NR2C2 | LRRK2 2992/4885RET 1627/4885DAPK3 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.